Used in research as a selective inhibitor of LSD1 (lysine-specific histone demethylase 1), showing potential in the development of treatments for acute myeloid leukemia and other hematologic malignancies. It modulates gene expression by preventing the demethylation of histone H3, leading to reactivation of silenced tumor suppressor genes. Currently investigated in preclinical and early clinical studies for its epigenetic regulatory effects in cancer therapy.